Search results for: abatacept

Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

Michele B. Kaufman, PharmD, BCGP | January 31, 2018

The FDA has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis…

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP | September 17, 2017

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

Linda Childers | September 17, 2017

A recent study, conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), examined whether the addition of abatacept, a drug that affects T cell activation, to standard prednisone treatment could reduce the risk of relapse in patients with giant cell arteritis (GCA).1 Although…

Abatacept Approved for Adult PsA

Michele B. Kaufman, PharmD, BCGP | July 31, 2017

The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…

FDA Requests Removal of Opana ER; Plus Abatacept’s New Dosing Option

Michele B. Kaufman, PharmD, BCGP | June 21, 2017

The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…

Similar RA Outcomes with Abatacept & Tocilizumab

Will Boggs, MD | August 17, 2015

NEW YORK (Reuters Health)—Clinical outcomes of rheumatoid arthritis (RA) are similar with abatacept and tocilizumab treatment, but the factors that predict efficacy differ for the two agents. “The recommendations for RA treatment from the U.S. and EU describe the use of abatacept and tocilizumab as first-line biologics along with anti-TNF (anti-tumor necrosis factor) inhibitors,” Dr….

Risky Business: Understanding What It Means to Be at Risk for RA

Jason Liebowitz, MD, FACR | November 20, 2024

The goal is to identify people at risk for RA &, perhaps, prevent its onset.

AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM

By Matthew A. Sherman, MD, MHSc, & Stacey E. Tarvin, MD, MS | November 10, 2024

Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…

Interventions to Delay RA Onset

Ruth Jessen Hickman, MD | October 9, 2024

Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.

2024 Research Updates in ANCA-Associated & IgA Vasculitis

Philip Seo, MD, MHS | October 7, 2024

Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.